Astria Therapeutics, Inc.
ATXS
$5.72
$0.122.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.39% | 13.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.02% | 1.99% | |||
| Operating Income | -25.02% | -1.99% | |||
| Income Before Tax | -31.54% | -4.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.54% | -4.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.54% | -4.45% | |||
| EBIT | -25.02% | -1.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -31.56% | -4.10% | |||
| Normalized Basic EPS | -31.55% | -4.11% | |||
| EPS Diluted | -31.56% | -4.10% | |||
| Normalized Diluted EPS | -31.55% | -4.11% | |||
| Average Basic Shares Outstanding | -0.02% | 0.34% | |||
| Average Diluted Shares Outstanding | -0.02% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||